Fbxo3 Inhibitor Program
Inflammatory Diseases
Pre-clinicalActive
Key Facts
About Koutif Therapeutics
Koutif Therapeutics is a private, pre-clinical stage biotech founded in 2021 and based in Cambridge, Massachusetts. The company is pioneering a novel approach to treating inflammatory diseases and oncology by developing small molecule inhibitors of the Fbxo3 protein, a previously untargeted E3 ligase within the ubiquitin-proteasome system. By inhibiting Fbxo3, Koutif's compounds aim to promote the degradation of key pro-inflammatory proteins like TRAFs and components of the NLRP3 inflammasome, potentially offering a new therapeutic mechanism for a wide range of conditions. The company is currently in the research and development phase, building on licensed academic discoveries to advance its pipeline.
View full company profileTherapeutic Areas
Other Inflammatory Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Amilo-5MER | Galmed Pharmaceuticals | Preclinical |
| Biosimilar to Simponi® (golimumab) | Teva | Under Regulatory Review |
| SRB1 | SunRock Biopharma | Discovery |
| CPR‑CYC‑202 | Chugai Pharmabody Research | Preclinical |
| Follow-on Compounds | Abivax | Research |
| CDX-622 | Celldex Therapeutics | Phase 1 |
| Avdoralimab (IPH5401) | Innate Pharma | Phase 2 |
| Izicopan (IFX-4) | InflaRx | Preclinical |
| IFX002 | InflaRx | Preclinical |